VEGFA and retinopathy of prematurity: The choice of ROP treatment (anti-VEGF injection or laser photocoagulation) and anti-VEGF agent (bevacizumab or ranibizumab) appears to have no significant effect on ocular or neurological outcomes, including neurodevelopment.